ZA200606065B - Acidic quinoline derivatives and their use for the prevention and/or treatment of hyperglycaemia-related pathologies - Google Patents
Acidic quinoline derivatives and their use for the prevention and/or treatment of hyperglycaemia-related pathologiesInfo
- Publication number
- ZA200606065B ZA200606065B ZA200606065A ZA200606065A ZA200606065B ZA 200606065 B ZA200606065 B ZA 200606065B ZA 200606065 A ZA200606065 A ZA 200606065A ZA 200606065 A ZA200606065 A ZA 200606065A ZA 200606065 B ZA200606065 B ZA 200606065B
- Authority
- ZA
- South Africa
- Prior art keywords
- hyperglycaemia
- acidic
- prevention
- treatment
- quinoline derivatives
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0315402A FR2864535B1 (fr) | 2003-12-24 | 2003-12-24 | Derives acides de quinoline et leurs applications en therapeutique |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200606065B true ZA200606065B (en) | 2007-12-27 |
Family
ID=34639610
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200606065A ZA200606065B (en) | 2003-12-24 | 2006-07-21 | Acidic quinoline derivatives and their use for the prevention and/or treatment of hyperglycaemia-related pathologies |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US7470708B2 (de) |
| EP (1) | EP1696924B1 (de) |
| JP (1) | JP4861828B2 (de) |
| KR (1) | KR20060123369A (de) |
| CN (1) | CN1893949A (de) |
| AR (1) | AR046980A1 (de) |
| AT (1) | ATE390136T1 (de) |
| AU (1) | AU2004308578B2 (de) |
| BR (1) | BRPI0417140A (de) |
| CA (1) | CA2551227C (de) |
| DE (1) | DE602004012770T2 (de) |
| ES (1) | ES2302058T3 (de) |
| FR (1) | FR2864535B1 (de) |
| MX (1) | MXPA06007082A (de) |
| RU (1) | RU2006126781A (de) |
| WO (1) | WO2005063244A1 (de) |
| ZA (1) | ZA200606065B (de) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0506133D0 (en) * | 2005-03-24 | 2005-05-04 | Sterix Ltd | Compound |
| AU2009243006B2 (en) * | 2008-05-01 | 2013-03-21 | Sirtris Pharmaceuticals, Inc. | Quinolines and related analogs as sirtuin modulators |
| PL228037B1 (pl) * | 2009-03-23 | 2018-02-28 | Marciniak Agnieszka Maria | Zastosowanie kwasu kynureninowego w zapobieganiu lub leczeniu chorób trzustki |
| US8450369B1 (en) * | 2011-08-02 | 2013-05-28 | CIP Kemicals, Corp. | Hypoglycemic oral drug for treating non-insulin dependent and insulin dependent diabetes |
| US8877811B1 (en) | 2011-08-02 | 2014-11-04 | CIP Kemicals, Corp. | Hypoglycemic oral drug for treating non-insulin dependent and insulin dependent diabetes |
| CN115124462B (zh) * | 2022-07-22 | 2023-08-22 | 浙江工业大学 | 2,3-二甲基-6,8-二氟喹啉-4-醚类化合物及其制备方法和应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5245046A (en) * | 1988-11-14 | 1993-09-14 | The Upjohn Company | α-amino-indole-3-acetic acids useful as anti-diabetic, anti-obesity and anti-atherosclerotic agents |
| ZA903588B (en) * | 1989-05-16 | 1991-02-27 | Merrell Dow Pharma | Excitatory amino acid antagonists |
| US5026700A (en) * | 1989-05-16 | 1991-06-25 | Merrell Dow Pharmaceuticals | Certain quinolines and thienopyridines as excitatory amino acid antagonists |
| JPH03161441A (ja) * | 1989-11-20 | 1991-07-11 | Senjiyu Seiyaku Kk | メイラード反応阻害剤 |
| US5728728A (en) * | 1996-04-10 | 1998-03-17 | Kozachuk; Walter E. | Methods of providing neuroprotection |
| US6025369A (en) * | 1996-05-03 | 2000-02-15 | The Board Of Regents Of The University Nebraska | N-methyl-D-aspartate (NMDA) receptor blockers for the prevention of atherosclerosis |
| FR2791263B1 (fr) * | 1999-03-26 | 2001-04-27 | Halina Zofia Malina | Preparations des medicaments bases sur une reponse immunitaire contre l'accumulation de proteines modifiees par l'acide xanthurenique |
| DE10005302A1 (de) * | 2000-02-07 | 2002-01-17 | Gruenenthal Gmbh | Substituierte 1,2,3,4-Tetrahydrochinolin-2-carbonsäurederivate |
| FR2827599A1 (fr) * | 2001-07-20 | 2003-01-24 | Neuro3D | Composes derives de quinoleine et quinoxaline,preparation et utilisations |
| AU2002950217A0 (en) * | 2002-07-16 | 2002-09-12 | Prana Biotechnology Limited | 8- Hydroxy Quinoline Derivatives |
| GB0226931D0 (en) * | 2002-11-19 | 2002-12-24 | Astrazeneca Ab | Chemical compounds |
-
2003
- 2003-12-24 FR FR0315402A patent/FR2864535B1/fr not_active Expired - Fee Related
-
2004
- 2004-12-01 AT AT04803419T patent/ATE390136T1/de not_active IP Right Cessation
- 2004-12-01 AU AU2004308578A patent/AU2004308578B2/en not_active Ceased
- 2004-12-01 ES ES04803419T patent/ES2302058T3/es active Active
- 2004-12-01 BR BRPI0417140-3A patent/BRPI0417140A/pt not_active IP Right Cessation
- 2004-12-01 JP JP2006545961A patent/JP4861828B2/ja not_active Expired - Fee Related
- 2004-12-01 KR KR1020067012375A patent/KR20060123369A/ko not_active Application Discontinuation
- 2004-12-01 US US10/584,151 patent/US7470708B2/en not_active Expired - Fee Related
- 2004-12-01 WO PCT/EP2004/013662 patent/WO2005063244A1/en active IP Right Grant
- 2004-12-01 CN CNA2004800375844A patent/CN1893949A/zh active Pending
- 2004-12-01 MX MXPA06007082A patent/MXPA06007082A/es not_active Application Discontinuation
- 2004-12-01 RU RU2006126781/15A patent/RU2006126781A/ru not_active Application Discontinuation
- 2004-12-01 DE DE602004012770T patent/DE602004012770T2/de active Active
- 2004-12-01 EP EP04803419A patent/EP1696924B1/de active Active
- 2004-12-01 CA CA2551227A patent/CA2551227C/en not_active Expired - Fee Related
- 2004-12-22 AR ARP040104837A patent/AR046980A1/es not_active Application Discontinuation
-
2006
- 2006-07-21 ZA ZA200606065A patent/ZA200606065B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1696924B1 (de) | 2008-03-26 |
| DE602004012770T2 (de) | 2009-04-09 |
| DE602004012770D1 (de) | 2008-05-08 |
| EP1696924A1 (de) | 2006-09-06 |
| MXPA06007082A (es) | 2006-08-23 |
| US7470708B2 (en) | 2008-12-30 |
| FR2864535B1 (fr) | 2006-12-22 |
| KR20060123369A (ko) | 2006-12-01 |
| BRPI0417140A (pt) | 2007-02-21 |
| JP4861828B2 (ja) | 2012-01-25 |
| AU2004308578B2 (en) | 2010-11-11 |
| AR046980A1 (es) | 2006-01-04 |
| CN1893949A (zh) | 2007-01-10 |
| ATE390136T1 (de) | 2008-04-15 |
| US20070149566A1 (en) | 2007-06-28 |
| RU2006126781A (ru) | 2008-01-27 |
| CA2551227A1 (en) | 2005-07-14 |
| WO2005063244A1 (en) | 2005-07-14 |
| CA2551227C (en) | 2013-03-12 |
| FR2864535A1 (fr) | 2005-07-01 |
| AU2004308578A1 (en) | 2005-07-14 |
| JP2007516986A (ja) | 2007-06-28 |
| ES2302058T3 (es) | 2008-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUS1500034I1 (hu) | Indolidon-származékok fibrózisos betegségek kezelésére vagy megelõzésére | |
| HK1152474A1 (en) | Methods and compositions for the prevention and treatment of sepsis | |
| EP1644021A4 (de) | Verfahren und zusammensetzungen zur behandlung von gastrointestinalen störungen | |
| IL174577A0 (en) | Tissue protective cytokines for the treatment and prevention of sepsis and the formation of adhesions | |
| ZA200707472B (en) | Diosmetin derivatives for the treatment and prevention of thrombotic pathologies | |
| EP1711197A4 (de) | Verfahren und zusammensetzungen für die prävention und behandlung entzündlicher erkrankungen oder zustände | |
| IL184124A0 (en) | Medicaments for the treatment or prevention of fibrotic diseases | |
| GB2418025B (en) | Device for the prevention or treatment of ulcers | |
| ZA200800981B (en) | Use of SDF-1 for the treatment and/or prevention of neurological diseases | |
| ZA200606065B (en) | Acidic quinoline derivatives and their use for the prevention and/or treatment of hyperglycaemia-related pathologies | |
| SI1487828T1 (sl) | Morfolinil-sečninski derivati za uporabo pri zdravljenu vnetnih bolezni | |
| HK1083732A1 (en) | Compounds for the treatment of tobacco dependence and withdrawal | |
| EP1812797A4 (de) | Zusammensetzungen und verfahren zur behandlung und vorbeugung von hyperproliferationskrankheiten | |
| PL375564A1 (en) | Substituted 5-chroman-5-yl-ethylamine compounds and their use for the treatment of glaucoma | |
| EP1671648A4 (de) | Prävention und behandlung von gvhd | |
| SI1680405T1 (sl) | Bengamidni derivati in njihova uporaba za zdravljenje rakavih bolezni | |
| IL143903A0 (en) | Use of phanquinone for the treatment or prevention of memory impairment | |
| GT200200281A (es) | Metodos y composiciones para el tratamiento de patologias respiratorias | |
| IL190842A0 (en) | Use of sdf-1 for the treatment and/or prevention of neurological diseases | |
| EP1581246A4 (de) | Porphyrin-derivate, verfahren zu ihrer herstellung und ihre verwendung in radioimmunotherapie | |
| SI1644021T1 (sl) | Postopki in sestavki za zdravljenje gastrointestinalnih motenj |